Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

SHTAC is critically appraising manufacturer’s submission to NICE on new drug for multiple sclerosis

Published: 7 October 2013
Nervous system

SHTAC is assessing the clinical-effectiveness and cost-effectiveness of alemtuzumab for the treatment of relapsing remitting multiple sclerosis for the National Institute for Health and Care Excellence (NICE) Single Technology Appraisal process.

Multiple sclerosis (MS) is a chronic, neurodegenerative disorder which leads, in most patients, to progressive neurological impairment and severe disability. Approximately 100,000 people in the UK have MS. Currently there is no cure for MS and treatments available aim to reduce the frequency and severity of relapses. Alemtuzumab is administered by intravenous infusion and is given over 5 days in the first year of treatment, and over 3 days in the second year of treatment.

NICE is expected to issue guidance on alemtuzumab to the health service in England and Wales in April 2014.

For more information on SHTAC's research on multiple sclerosis our Research page.


We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.